135 related articles for article (PubMed ID: 29560416)
1. An assessment of neuronal calcium sensor-1 and response to neoadjuvant chemotherapy in breast cancer patients.
Moore LM; Wilkinson R; Altan M; Toki M; Carvajal-Hausdorf DE; McGuire J; Ehrlich BE; Rimm DL
NPJ Breast Cancer; 2018; 4():6. PubMed ID: 29560416
[TBL] [Abstract][Full Text] [Related]
2. SIRT5 as a biomarker for response to anthracycline-taxane-based neoadjuvant chemotherapy in triple-negative breast cancer.
Xu L; Che X; Wu Y; Song N; Shi S; Wang S; Li C; Zhang L; Zhang X; Qu X; Teng Y
Oncol Rep; 2018 May; 39(5):2315-2323. PubMed ID: 29565454
[TBL] [Abstract][Full Text] [Related]
3. Calcium Sensor, NCS-1, Promotes Tumor Aggressiveness and Predicts Patient Survival.
Moore LM; England A; Ehrlich BE; Rimm DL
Mol Cancer Res; 2017 Jul; 15(7):942-952. PubMed ID: 28275088
[TBL] [Abstract][Full Text] [Related]
4. Polymorphisms in microRNA let-7 binding sites of the
Du Y; Zhou L; Lin Y; Yin K; Yin W; Lu J
Ann Transl Med; 2019 Apr; 7(7):138. PubMed ID: 31157259
[TBL] [Abstract][Full Text] [Related]
5. Pathological response and clinical outcomes in operable triple-negative breast cancer with cisplatin added to standard neoadjuvant chemotherapy.
Georgy JT; Singh A; John AO; Joel A; Andrews AG; Thumaty DB; Rebekah G; Sigamani E; Chandramohan J; Manipadam MT; Cherian AJ; Abraham DT; Paul MJ; Balakrishnan R; Backianathan S; Chacko RT
Klin Onkol; 2021; 34(1):49-55. PubMed ID: 33657819
[TBL] [Abstract][Full Text] [Related]
6. A MicroRNA Expression Signature In Taxane-anthracycline-Based Neoadjuvant Chemotherapy Response.
Zheng Y; Li S; Boohaker RJ; Liu X; Zhu Y; Zhai L; Li H; Gu F; Fan Y; Lang R; Liu F; Qian X; Xu B; Fu L
J Cancer; 2015; 6(7):671-7. PubMed ID: 26078798
[TBL] [Abstract][Full Text] [Related]
7. Tau expression correlated with breast cancer sensitivity to taxanes-based neoadjuvant chemotherapy.
Wang K; Deng QT; Liao N; Zhang GC; Liu YH; Xu FP; Zu J; Li XR; Wu YL
Tumour Biol; 2013 Feb; 34(1):33-8. PubMed ID: 22976542
[TBL] [Abstract][Full Text] [Related]
8. DJ-1 protein expression as a predictor of pathological complete remission after neoadjuvant chemotherapy in breast cancer patients.
Kawate T; Iwaya K; Kikuchi R; Kaise H; Oda M; Sato E; Hiroi S; Matsubara O; Kohno N
Breast Cancer Res Treat; 2013 May; 139(1):51-9. PubMed ID: 23592371
[TBL] [Abstract][Full Text] [Related]
9. Antitumor activity and efficacy of shorter
Lobefaro R; Zattarin E; Nichetti F; Prisciandaro M; Ligorio F; Brambilla M; Sepe P; Corti F; Peverelli G; Ottini A; Beninato T; Mazzeo L; Rea CG; Mariani G; de Braud F; Bianchi GV; Vernieri C; Capri G
Ther Adv Med Oncol; 2020; 12():1758835920970081. PubMed ID: 33335565
[TBL] [Abstract][Full Text] [Related]
10. A single-nucleotide polymorphism of the beta 2-adrenergic receptor gene can predict pathological complete response to taxane- and platinum-based neoadjuvant chemotherapy in breast cancer.
Du Y; Yan T; Zhou L; Yin W; Lu J
Breast Cancer (Dove Med Press); 2018; 10():201-206. PubMed ID: 30568487
[TBL] [Abstract][Full Text] [Related]
11. Neoadjuvant triweekly nanoparticle albumin-bound paclitaxel followed by epirubicin and cyclophosphamide for Stage II/III HER2-negative breast cancer: evaluation of efficacy and safety.
Shimada H; Ueda S; Saeki T; Shigekawa T; Takeuchi H; Hirokawa E; Sugitani I; Sugiyama M; Takahashi T; Matsuura K; Yamane T; Kuji I; Hasebe T; Osaki A
Jpn J Clin Oncol; 2015 Jul; 45(7):642-9. PubMed ID: 25989989
[TBL] [Abstract][Full Text] [Related]
12. An Immune-Associated Genomic Signature Effectively Predicts Pathologic Complete Response to Neoadjuvant Paclitaxel and Anthracycline-Based Chemotherapy in Breast Cancer.
Fu C; Liu Y; Han X; Pan Y; Wang HQ; Wang H; Dai H; Yang W
Front Immunol; 2021; 12():704655. PubMed ID: 34526986
[TBL] [Abstract][Full Text] [Related]
13. Identification of biology-based breast cancer types with distinct predictive and prognostic features: role of steroid hormone and HER2 receptor expression in patients treated with neoadjuvant anthracycline/taxane-based chemotherapy.
Darb-Esfahani S; Loibl S; Müller BM; Roller M; Denkert C; Komor M; Schlüns K; Blohmer JU; Budczies J; Gerber B; Noske A; du Bois A; Weichert W; Jackisch C; Dietel M; Richter K; Kaufmann M; von Minckwitz G
Breast Cancer Res; 2009; 11(5):R69. PubMed ID: 19758440
[TBL] [Abstract][Full Text] [Related]
14. Nab-paclitaxel versus solvent-based paclitaxel in neoadjuvant chemotherapy for early breast cancer (GeparSepto-GBG 69): a randomised, phase 3 trial.
Untch M; Jackisch C; Schneeweiss A; Conrad B; Aktas B; Denkert C; Eidtmann H; Wiebringhaus H; Kümmel S; Hilfrich J; Warm M; Paepke S; Just M; Hanusch C; Hackmann J; Blohmer JU; Clemens M; Darb-Esfahani S; Schmitt WD; Dan Costa S; Gerber B; Engels K; Nekljudova V; Loibl S; von Minckwitz G; ;
Lancet Oncol; 2016 Mar; 17(3):345-356. PubMed ID: 26869049
[TBL] [Abstract][Full Text] [Related]
15. Specific kinesin expression profiles associated with taxane resistance in basal-like breast cancer.
Tan MH; De S; Bebek G; Orloff MS; Wesolowski R; Downs-Kelly E; Budd GT; Stark GR; Eng C
Breast Cancer Res Treat; 2012 Feb; 131(3):849-58. PubMed ID: 21479552
[TBL] [Abstract][Full Text] [Related]
16. Identification of markers of taxane sensitivity using proteomic and genomic analyses of breast tumors from patients receiving neoadjuvant paclitaxel and radiation.
Bauer JA; Chakravarthy AB; Rosenbluth JM; Mi D; Seeley EH; De Matos Granja-Ingram N; Olivares MG; Kelley MC; Mayer IA; Meszoely IM; Means-Powell JA; Johnson KN; Tsai CJ; Ayers GD; Sanders ME; Schneider RJ; Formenti SC; Caprioli RM; Pietenpol JA
Clin Cancer Res; 2010 Jan; 16(2):681-90. PubMed ID: 20068102
[TBL] [Abstract][Full Text] [Related]
17. MicroRNAs miR-7 and miR-340 predict response to neoadjuvant chemotherapy in breast cancer.
Raychaudhuri M; Bronger H; Buchner T; Kiechle M; Weichert W; Avril S
Breast Cancer Res Treat; 2017 Apr; 162(3):511-521. PubMed ID: 28181130
[TBL] [Abstract][Full Text] [Related]
18. Evidence-based use of neoadjuvant taxane in operable and inoperable breast cancer.
Estévez LG; Gradishar WJ
Clin Cancer Res; 2004 May; 10(10):3249-61. PubMed ID: 15161677
[TBL] [Abstract][Full Text] [Related]
19. CD10 expression as a potential predictor of pathological complete response in ER-negative and triple-negative breast cancer patients treated with anthracycline-based neoadjuvant chemotherapy.
Dimitrov G; Shousha S; Troianova P
Exp Mol Pathol; 2024 Feb; 135():104885. PubMed ID: 38281565
[TBL] [Abstract][Full Text] [Related]
20. Phase II open-label study of bevacizumab combined with neoadjuvant anthracycline and taxane therapy for locally advanced breast cancer.
Clavarezza M; Turazza M; Aitini E; Saracchini S; Garrone O; Durando A; De Placido S; Bisagni G; Levaggi A; Bighin C; Restuccia E; Scalamogna R; Galli A; Del Mastro L
Breast; 2013 Aug; 22(4):470-5. PubMed ID: 23642526
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
